Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells.

Kaehler M, Ruemenapp J, Gonnermann D, Nagel I, Bruhn O, Haenisch S, Ammerpohl O, Wesch D, Cascorbi I, Bruckmueller H.

Oncotarget. 2017 Sep 26;8(54):92018-92031. doi: 10.18632/oncotarget.21272. eCollection 2017 Nov 3.

2.

OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications.

Böhm R, von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, Höcker J.

PLoS One. 2016 Jun 21;11(6):e0157753. doi: 10.1371/journal.pone.0157753. eCollection 2016.

3.

Length variants of the ABCB1 3'-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance.

Bruhn O, Drerup K, Kaehler M, Haenisch S, Röder C, Cascorbi I.

Pharmacogenomics. 2016 Mar;17(4):327-40. doi: 10.2217/pgs.15.175. Epub 2016 Feb 19.

PMID:
26895184
4.

Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.

Bruhn O, Cascorbi I.

Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1337-54. doi: 10.1517/17425255.2014.952630. Epub 2014 Aug 27. Review.

PMID:
25162314
5.

Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

Nies AT, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M, Pott C, Hofmann U, Volk C, Hu S, Baker SD, Sparreboom A, Ruth P, Koepsell H, Schwab M.

Clin Cancer Res. 2014 Feb 15;20(4):985-94. doi: 10.1158/1078-0432.CCR-13-1999. Epub 2013 Dec 18.

6.

Challenges in pharmacogenetics.

Cascorbi I, Bruhn O, Werk AN.

Eur J Clin Pharmacol. 2013 May;69 Suppl 1:17-23. doi: 10.1007/s00228-013-1492-x. Epub 2013 May 3. Review.

PMID:
23640184
7.

MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.

Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I.

Pharmacogenet Genomics. 2012 Mar;22(3):198-205. doi: 10.1097/FPC.0b013e328350012b.

PMID:
22241070
8.

In vitro potential of equine DEFA1 and eCATH1 as alternative antimicrobial drugs in rhodococcosis treatment.

Schlusselhuber M, Jung S, Bruhn O, Goux D, Leippe M, Leclercq R, Laugier C, Grötzinger J, Cauchard J.

Antimicrob Agents Chemother. 2012 Apr;56(4):1749-55. doi: 10.1128/AAC.05797-11. Epub 2012 Jan 9.

9.

Antimicrobial peptides and proteins of the horse--insights into a well-armed organism.

Bruhn O, Grötzinger J, Cascorbi I, Jung S.

Vet Res. 2011 Sep 2;42:98. doi: 10.1186/1297-9716-42-98. Review.

10.

Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379.

Haenisch S, Laechelt S, Bruckmueller H, Werk A, Noack A, Bruhn O, Remmler C, Cascorbi I.

Mol Pharmacol. 2011 Aug;80(2):314-20. doi: 10.1124/mol.110.070714. Epub 2011 May 3.

11.

The repertoire of equine intestinal alpha-defensins.

Bruhn O, Paul S, Tetens J, Thaller G.

BMC Genomics. 2009 Dec 23;10:631. doi: 10.1186/1471-2164-10-631.

12.

Antimicrobial properties of the equine alpha-defensin DEFA1 against bacterial horse pathogens.

Bruhn O, Cauchard J, Schlusselhuber M, Gelhaus C, Podschun R, Thaller G, Laugier C, Leippe M, Grötzinger J.

Vet Immunol Immunopathol. 2009 Jul 15;130(1-2):102-6. doi: 10.1016/j.vetimm.2009.01.005. Epub 2009 Jan 23.

PMID:
19211153
13.

A novel horse alpha-defensin: gene transcription, recombinant expression and characterization of the structure and function.

Bruhn O, Regenhard P, Michalek M, Paul S, Gelhaus C, Jung S, Thaller G, Podschun R, Leippe M, Grötzinger J, Kalm E.

Biochem J. 2007 Oct 15;407(2):267-76.

14.

Assignment of the equine S100A7 gene (psoriasin 1) to chromosome 5p12-->p13 by fluorescence in situ hybridization and radiation hybrid mapping.

Leeb T, Bruhn O, Philipp U, Kuiper H, Regenhard P, Paul S, Distl O, Chowdhary BP, Kalm E, Looft C.

Cytogenet Genome Res. 2005;109(4):533. No abstract available.

PMID:
15906470
15.

[Prehospital treatment. They must do it like we do it. Interview by Peter Skeel Hjorth].

Bruhn O.

Sygeplejersken. 1992 Nov 11;92(46):4-9, 13. Danish. No abstract available.

PMID:
1297225

Supplemental Content

Support Center